Endocrine Abstracts

The stable somatostatin analog octreotide has been successfully used for imaging and treatment of a variety of human tumors. Octreotide treatment has been reported of limited value in pheochromocytoma (PHEO). PHEOs often express more than one somatostatin receptor, and it is uncertain by which receptor subtype the functional responses of octreotide are mediated. A recent study showed by immunohistochemical staining that vast majority of tumors (90%) were positive for sst(3), i...

Recently it has been shown that somatostatin (SST) might be of therapeutic value in the treatment of active Graves’ophthalmopathy (GO). SST and somatostatin receptors (sst) transcripts are expressed and functional in cultured orbital fibroblasts deriving from GO patients (FGO). Octreotide, the SST analogue currently used is able to inhibit in vitro growth and activity of FGO. New analogues with wider sst-affinity are now available for in vitro experim...

Autoimmune chronic thyroid disease (AITD) is associated with atrophic gastritis (CAG) in 29–42% of the cases. CAG and the consequent hypergastrinemia, listed as precancerous lesion, can predispose to neuroendocrine cells hyperplasia and the development of neuroendocrine gastric tumors (NET). Aim of this study was to evaluate the association of AITD with risk of gastric NET and the efficacy of somatostatin analogues treatment.Patients: From 2009 to 2...